MARKET

APRE

APRE

Aprea Therapeutics, Inc.
NASDAQ
0.4681
-0.0065
-1.37%
Closed 16:00 12/07 EST
OPEN
0.5400
PREV CLOSE
0.4746
HIGH
0.5400
LOW
0.4385
VOLUME
138.00K
TURNOVER
49.37K
52 WEEK HIGH
4.700
52 WEEK LOW
0.3310
MARKET CAP
24.81M
P/E (TTM)
-0.0905
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 4h ago
BRIEF-Aprea Therapeutics Says Staff Of Nasdaq Determined That Co Has Regained Compliance With Minimum $10 Mln Stockholders' Equity Requirement Rule
Reuters · 11/16 22:42
Why Tattooed Chef Shares Dipped Around 15%; Here Are 95 Biggest Movers From Friday
Benzinga · 11/14 07:35
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 11/11 19:59
Why Compass Shares Are Trading Higher By Over 56%? Here Are 63 Stocks Moving In Friday's Mid-Day Session
Benzinga · 11/11 17:48
Aprea Therapeutics GAAP EPS of -$0.12 misses by $0.03
Seekingalpha · 11/09 22:22
Aprea Therapeutics Q3 EPS $(0.12) Up From $(0.45) YoY
Benzinga · 11/09 22:12
HC Wainwright & Co. Assumes Aprea Therapeutics at Buy, Announces Price Target of $3
HC Wainwright & Co. analyst Joseph Pantginis assumes Aprea Therapeutics (NASDAQ:APRE) with a Buy rating and announces Price Target of $3.
Benzinga · 10/10 10:20
More
About APRE
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on developing and commercializing novel cancer therapeutics that reactivate mutant protein 53 (p53) tumor suppressor protein. The Company's lead product candidate, APR-246, or eprenetapopt, is a small molecule p53 reactivator that is in clinical development for hematologic malignancies, including myelodysplastic syndromes, or myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). The Company's APR-548 is a second generation p53 reactivator that is a unique analog of eprenetapopt and therefore a pro-drug of MQ. APR-548 exhibits high oral bioavailability in preclinical testing and is being developed in an oral dosage form. The Company has initiated a Phase I clinical trial testing APR-548 in relapsed/refractory MDS and AML. Its solid tumor program includes its clinical trial evaluating eprenetapopt with anti-PD-1 therapy in advanced solid tumors.

Webull offers kinds of Aprea Therapeutics Inc stock information, including NASDAQ:APRE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APRE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading APRE stock methods without spending real money on the virtual paper trading platform.